Astellas vs. Zydus: Consent Judgment Blocks Generic Mirabegron
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Astellas Pharma, Inc. v. Zydus Lifesciences Limited et al. |
| Case Number | 1:24-cv-01069-JFB-EGT (D. Del.) |
| Court | District Court for the District of Delaware |
| Duration | Sep 2024 – Feb 2026 1 year 5 months |
| Outcome | Plaintiff Win — Injunctive Relief |
| Patents at Issue | |
| Accused Products | Generic Mirabegron Extended-Release Tablets (25 mg & 50 mg) |
Case Overview
The Parties
⚖️ Plaintiff
A global pharmaceutical company headquartered in Japan, holding an extensive patent portfolio for its branded drug Myrbetriq®.
🛡️ Defendant
One of India’s largest pharmaceutical manufacturers, with a U.S. subsidiary, Zydus Pharmaceuticals (USA) Inc., that filed the ANDA.
Patents at Issue
This landmark case involved four U.S. patents covering formulation, composition, and/or method-of-use aspects of mirabegron extended-release technology. These utility patents are registered with the U.S. Patent and Trademark Office (USPTO) and protect the functional aspects of the drug.
- • US 10,842,780 — Formulation aspects of mirabegron extended-release
- • US 11,707,451 — Composition claims related to mirabegron tablets
- • US 12,059,409 — Method-of-use patent for overactive bladder treatment
- • US 12,097,189 — Further claims protecting mirabegron ER technology
Developing a generic drug?
Check if your formulation might infringe these or related patents before seeking FDA approval.
The Verdict & Legal Analysis
Outcome
The Delaware District Court entered a **consent judgment** on February 19, 2026. Zydus formally admitted to the validity and infringement of all four asserted patents. No specific monetary damages were awarded; the resolution’s principal remedy is injunctive in nature, blocking generic entry until patent expiration.
Key Legal Issues
This negotiated consent judgment reinforced Astellas’s pharmaceutical patent portfolio. Zydus is enjoined from making, using, selling, or importing its ANDA products through the expiration of all four patents, including any patent term extensions, pediatric exclusivity, or other regulatory exclusivities. This outcome demonstrates the effectiveness of a proactive, multi-patent lifecycle management strategy in Hatch-Waxman litigation, even against a Paragraph IV certification.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this pharmaceutical litigation.
- View all related patents in this therapeutic space
- See which companies are most active in related pharma patents
- Understand claim construction patterns for drug formulations
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own pharmaceutical compound or formulation.
- Input your drug formulation or technical features
- AI identifies potentially blocking patents
- Get actionable infringement risk assessment report
High Risk Area
Mirabegron extended-release formulations
4 Asserted Patents
Covering formulation & method-of-use
Formulation-Around Options
Available for some claims
✅ Key Takeaways
Consent judgments securing bilateral validity and infringement admissions across multiple patents represent a high-value litigation outcome for branded pharmaceutical companies.
Search related case law →Consolidated multi-case management in Delaware enables efficient resolution of complex, multi-patent ANDA disputes.
Explore precedents →Frequently Asked Questions
Four U.S. patents: No. 10,842,780; No. 11,707,451; No. 12,059,409; and No. 12,097,189, all relating to mirabegron extended-release tablet technology.
The parties entered a consent judgment in which Zydus formally admitted validity and infringement of all four asserted patents, agreeing not to market its generic mirabegron products through patent expiration.
It reinforces the value of coordinated continuation prosecution and multi-action ANDA litigation as tools for securing comprehensive, multi-patent protection for branded pharmaceutical products.
Ready to Strengthen Your Pharmaceutical IP Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, analyse competitive landscapes, and manage patent portfolios with AI-powered precision.
References
- PACER — U.S. Federal Courts Records (Case No. 1:24-cv-01069-JFB-EGT)
- USPTO Patent Center — U.S. Patent No. 12,097,189
- U.S. Patent and Trademark Office — General Patent Resources
- World Intellectual Property Organization — Intellectual Property Overview
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.